Precision Biology solutions focused on multiplexed analysis of cells and tissue with applications in both research and clinical diagnostics

RareCyte News

RareCyte® announces a new dual biomarker liquid biopsy assay for androgen receptor splice variant 7 (ARv7) and the neuroendocrine marker, synaptophysin (SYP)
more →

RareCyte® announces the Orion™ spatial biology platform with breakthrough technology for same-day highly multiplexed tissue analysis
more →

Upcoming Events

Rarecyte® will presenting a 20 minute talk on the Orion platform as well as a 1 hour technology showcase event during 2021 Molecular Med Tri-Con in Feb 16-18, 2021.
more →

Pharma Programs

“The RareCyte CTC system has been analytically validated in our CAP/CLIA Laboratory and the validation and acceptance criteria met the needs of the clinical drug study team. In partnership with a global CRO, the CTC workflow is being successfully implemented.”

   – Jeff Fill, Senior Director, Diagnostic and Experimental Pathology, Eli Lilly and Company
more →